Analyst Price Target is $13.80
▲ +4.94% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Fusion Pharmaceuticals in the last 3 months. The average price target is $13.80, with a high forecast of $16.00 and a low forecast of $12.00. The average price target represents a 4.94% upside from the last price of $13.15.
Current Consensus is
The current consensus among 7 polled investment analysts is to buy stock in Fusion Pharmaceuticals. This Buy consensus rating has held steady for over two years.
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. Its lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it develops FPI-1966 for the treatment of multiple cancers, including colorectal, ovarian, bladder, and head and neck cancers. The company has a strategic collaboration agreement with AstraZeneca UK Limited to discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. Fusion Pharmaceuticals Inc. was incorporated in 2014 and is headquartered in Hamilton, Canada.